



FOLFIRINOX versus gemcitabine/nab-paclitaxel for treatment of



ALL

IMAGES

VIDEOS

关闭取词

16,100 Results

Any time ▾

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1011923>



Prognosis

Research

Scope

Preparation

Administration



Characteristic	FFX	Gem
Age, yr	62	62
Sex, %		
Male	91	91
Female	9	9
ECOG performance score, %		
0	91	91
1	9	9
ECOG performance score, %		
0	91	91
1	9	9
ECOG performance score, %		
0	91	91
1	9	9
ECOG performance score, %		
0	91	91
1	9	9

Pancreatic adenocarcinoma was the fourth leading cause of death from cancer in the United States in 2010,¹ and it carries a grim prognosis: the 5-year survival rate is 6% in Europe and the United States.^{1,2} Gemcitabine became the reference regimen for advanced pancreatic cancer after a randomized trial showed significant improvement in the median overall survival as compared with fluorouracil administered as an intravenous...

See more on nejm.org

Cited by: 4258

Author: Thierry Conroy, Françoise Desseigne, Ma...

Publish Year: 2011

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for ...

<https://link.springer.com/article/10.1007/s00280-018-3611-y> ▾

May 30, 2018 · Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital.

Cited by: 10

Author: Junko Tahara, Kyoko Shimizu, Nao Otsu...

Publish Year: 2018

Real-world outcomes of FOLFIRINOX vs gemcitabine and ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2705>

In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) have been publicly funded for first-line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015.

Folfirinox (FFX) versus gemcitabine with nab-paclitaxel ...

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.414

Folfirinox (FFX) versus gemcitabine with nab-paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.

Cited by: 1

Author: Ivan Barrera, Sabina Hamalova, Jill Range...

Publish Year: 2018



Match Overview

1	Crossref 187 words I Cho, H Kang, J Jo, H Lee, M Chung, J Park, S Park, S Song, M Park, C An, S Jung, S Bang. "P-161FOLFIRINOX versus	4%
2	Crossref 58 words In Rae Cho, Huapyeong Kang, Jung Hyun Jo, Hee Seung Lee et al. "Efficacy and treatment-related adverse events of ge	1%
3	Internet 34 words crawled on 15-Apr-2018 mdanderson.influent.utsystem.edu	1%
4	Internet 26 words s3-eu-west-1.amazonaws.com	1%
5	Internet 16 words crawled on 11-Jul-2019 www.wjgnet.com	<1%
6	Internet 15 words crawled on 16-Sep-2019 cardiab.biomedcentral.com	<1%
7	Internet 13 words crawled on 28-Sep-2019 www.haematologica.org	<1%
8	Internet 12 words crawled on 11-Jun-2019 www.tandfonline.com	<1%
9	Internet 12 words crawled on 05-Oct-2019 f6publishing.blob.core.windows.net	<1%

⁹
Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 51979

Manuscript Type: ORIGINAL ARTICLE

FOLFIRINOX versus gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: ³**Single-center cohort study**

In Rae Cho, Huapyeong Kang, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Chansik An, Mi-Suk Park, Seungmin Bang

Abstract

BACKGROUND

15,900 Results

Any time ▾

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1011923>

Prognosis

Research

Scope

Preparation

Administration



Characteristic	FOLFIRINOX	Gemcitabine
Age, mean (SD)	62 (10)	62 (10)
Sex, %		
Male	95	95
Female	5	5
Race, %		
White	95	95
Black	5	5
Hispanic	0	0
Asian	0	0
Other	0	0
ECOG performance, %		
0	95	95
1	5	5
2	0	0
3	0	0
4	0	0
5	0	0
6	0	0
7	0	0
8	0	0
9	0	0
10	0	0
11	0	0
12	0	0
13	0	0
14	0	0
15	0	0
16	0	0
17	0	0
18	0	0
19	0	0
20	0	0
21	0	0
22	0	0
23	0	0
24	0	0
25	0	0
26	0	0
27	0	0
28	0	0
29	0	0
30	0	0
31	0	0
32	0	0
33	0	0
34	0	0
35	0	0
36	0	0
37	0	0
38	0	0
39	0	0
40	0	0
41	0	0
42	0	0
43	0	0
44	0	0
45	0	0
46	0	0
47	0	0
48	0	0
49	0	0
50	0	0
51	0	0
52	0	0
53	0	0
54	0	0
55	0	0
56	0	0
57	0	0
58	0	0
59	0	0
60	0	0
61	0	0
62	0	0
63	0	0
64	0	0
65	0	0
66	0	0
67	0	0
68	0	0
69	0	0
70	0	0
71	0	0
72	0	0
73	0	0
74	0	0
75	0	0
76	0	0
77	0	0
78	0	0
79	0	0
80	0	0
81	0	0
82	0	0
83	0	0
84	0	0
85	0	0
86	0	0
87	0	0
88	0	0
89	0	0
90	0	0
91	0	0
92	0	0
93	0	0
94	0	0
95	0	0
96	0	0
97	0	0
98	0	0
99	0	0
100	0	0

Pancreatic adenocarcinoma was the fourth leading cause of death from cancer in the United States in 2010,¹ and it carries a grim prognosis: the 5-year survival rate is 6% in Europe and the United States.^{1,2} Gemcitabine became the reference regimen for advanced pancreatic cancer after a randomized trial showed significant improvement in the median overall survival as compared with fluorouracil administered as an intravenous...

[See more on nejm.org](#)

Cited by: 4258

Author: Thierry Conroy, Françoise Desseigne, Ma...

Publish Year: 2011

Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for ...

<https://link.springer.com/article/10.1007/s00280-018-3611-y>

May 30, 2018 · Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events.

Cited by: 10

Author: Junko Tahara, Kyoko Shimizu, Nao Otsu...

Publish Year: 2018

Real-world outcomes of FOLFIRINOX vs gemcitabine and ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2705>

In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) have been publicly funded for first-line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015. We examined the real-world effectiveness and safety of FFX vs GnP for advanced pancreatic cancer, and in uLAPC and mPC.

Comparative Effectiveness of nab-Paclitaxel Plus ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182639>

Sep 12, 2018 · Braiteh F, Patel MB, Parisi M, et al. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting